FDA relies too much on tipoffs, not enough on drug checks

A drug-company whistle-blower last month pocketed $96 million -- her share of the money Medicare and Medicaid paid for tainted drugs. The fee is way too high -- employees will drop a dime for far less. And the FDA would do better to improve inspections rather than rely so heavily on whistle-blowers. (Full article: 375 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

• $4.95 1 article
• $9.95 4 articles
• $25.95 Monthly